Literature DB >> 12037041

Antimicrobial susceptibility testing of Bacillus anthracis: comparison of results obtained by using the National Committee for Clinical Laboratory Standards broth microdilution reference and Etest agar gradient diffusion methods.

M Jasmine Mohammed1, Chung K Marston, Tanja Popovic, Robbin S Weyant, Fred C Tenover.   

Abstract

We determined the patterns of antimicrobial susceptibility of 65 isolates of Bacillus anthracis (50 historical and 15 recent U.S. clinical isolates) to nine antimicrobial agents using the National Committee for Clinical Laboratory Standards (NCCLS) broth microdilution reference method. The results for the 50 historical B. anthracis isolates obtained by the broth microdilution method were compared to those generated by the Etest agar gradient diffusion method. One isolate of B. anthracis was beta-lactamase positive and resistant to penicillin (MIC, 128 microg/ml); a second isolate, which was beta-lactamase negative, was borderline penicillin resistant, with the penicillin MICs for the isolate varying from 0.12 to 0.25 microg/ml; and the remainder of the isolates were beta-lactamase negative and penicillin susceptible (MICs, <or=0.12 microg/ml). Approximately 78% of the isolates showed reduced susceptibility to ceftriaxone (MICs, >or=16 microg/ml). All B. anthracis isolates were susceptible to chloramphenicol (MICs, <or=8 microg/ml), ciprofloxacin (MICs, <or= 1 microg/ml), clindamycin (MICs, <or=0.5 microg/ml), rifampin (MICs, <or=0.5 microg/ml), tetracycline (MICs, <or=0.06 microg/ml), and vancomycin (MICs, <or=2 microg/ml) by use of NCCLS breakpoints for staphylococci. All 15 recent B. anthracis isolates from the United States were susceptible to penicillin, doxycycline, and ciprofloxacin. By use of the susceptibility breakpoint for staphylococci of <or=0.5 microg/ml, 97% of the B. anthracis isolates tested would have been categorized as intermediate to erythromycin. No statistically significant difference was found between the results of broth microdilution testing and the results of the Etest method for any of the antimicrobial agents tested; however, the results for penicillin obtained by the Etest were 1 to 9 dilutions lower than those obtained by the broth microdilution method. The differences in the penicillin MICs by the Etest method and the difficulties of reading the Etest results through the glass of a biological safety cabinet may limit the utility of this alternate susceptibility testing method for B. anthracis isolates.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12037041      PMCID: PMC130796          DOI: 10.1128/JCM.40.6.1902-1907.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

Review 1.  Bioterrorism: implications for the clinical microbiologist.

Authors:  W F Klietmann; K L Ruoff
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 2.  Anthrax.

Authors:  T C Dixon; M Meselson; J Guillemin; P C Hanna
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

Review 3.  Treatment of anthrax in man: history and current concepts.

Authors:  G B Knudson
Journal:  Mil Med       Date:  1986-02       Impact factor: 1.437

4.  Update: Interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-11-16       Impact factor: 17.586

5.  Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2001-10-26       Impact factor: 17.586

6.  Comparison of the Etest and the NCCLS-approved agar dilution method to detect metronidazole and clarithromycin resistant Helicobacter pylori.

Authors:  M S Osato; R Reddy; S G Reddy; R L Penland; D Y Graham
Journal:  Int J Antimicrob Agents       Date:  2001-01       Impact factor: 5.283

7.  Surveillance for adverse events associated with anthrax vaccination--U.S. Department of Defense, 1998-2000.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-04-28       Impact factor: 17.586

8.  Serious infections caused by Bacillus species.

Authors:  R Sliman; S Rehm; D M Shlaes
Journal:  Medicine (Baltimore)       Date:  1987-05       Impact factor: 1.889

9.  In vitro susceptibility of Bacillus spp. to selected antimicrobial agents.

Authors:  D J Weber; S M Saviteer; W A Rutala; C A Thomann
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

10.  Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States.

Authors:  J A Jernigan; D S Stephens; D A Ashford; C Omenaca; M S Topiel; M Galbraith; M Tapper; T L Fisk; S Zaki; T Popovic; R F Meyer; C P Quinn; S A Harper; S K Fridkin; J J Sejvar; C W Shepard; M McConnell; J Guarner; W J Shieh; J M Malecki; J L Gerberding; J M Hughes; B A Perkins
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more
  29 in total

1.  Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis.

Authors:  Isabel C Materon; Anne Marie Queenan; Theresa M Koehler; Karen Bush; Timothy Palzkill
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Beta-lactamase gene expression in a penicillin-resistant Bacillus anthracis strain.

Authors:  Yahua Chen; Fred C Tenover; Theresa M Koehler
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

3.  Antibiotic susceptibility and molecular diversity of Bacillus anthracis strains in Chad: detection of a new phylogenetic subgroup.

Authors:  Angaya Maho; Alexandra Rossano; Herbert Hächler; Anita Holzer; Esther Schelling; Jakob Zinsstag; Mahamat H Hassane; Bhen S Toguebaye; Ayayi J Akakpo; Matthew Van Ert; Paul Keim; Leo Kenefic; Joachim Frey; Vincent Perreten
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

4.  Antimicrobial Susceptibility Testing and Tentative Epidemiological Cutoff Values for Five Bacillus Species Relevant for Use as Animal Feed Additives or for Plant Protection.

Authors:  Yvonne Agersø; Birgitte Stuer-Lauridsen; Karin Bjerre; Michelle Geervliet Jensen; Eric Johansen; Mads Bennedsen; Elke Brockmann; Bea Nielsen
Journal:  Appl Environ Microbiol       Date:  2018-09-17       Impact factor: 4.792

5.  Hollow-fiber pharmacodynamic studies and mathematical modeling to predict the efficacy of amoxicillin for anthrax postexposure prophylaxis in pregnant women and children.

Authors:  Arnold Louie; Brian Vanscoy; Weiguo Liu; Robert Kulawy; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

6.  In vitro efficacy of new antifolates against trimethoprim-resistant Bacillus anthracis.

Authors:  Esther W Barrow; Jürg Dreier; Stefan Reinelt; Philip C Bourne; William W Barrow
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

7.  Beta-lactamase genes of the penicillin-susceptible Bacillus anthracis Sterne strain.

Authors:  Yahua Chen; Janice Succi; Fred C Tenover; Theresa M Koehler
Journal:  J Bacteriol       Date:  2003-02       Impact factor: 3.490

8.  MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest.

Authors:  Peter C B Turnbull; Nicky M Sirianni; Carlos I LeBron; Marian N Samaan; Felicia N Sutton; Anatalio E Reyes; Leonard F Peruski
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

9.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  Public health in the time of bioterrorism.

Authors:  Bradley A Perkins; Tanja Popovic; Kevin Yeskey
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.